<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599611</url>
  </required_header>
  <id_info>
    <org_study_id>pkv</org_study_id>
    <nct_id>NCT01599611</nct_id>
  </id_info>
  <brief_title>Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study</brief_title>
  <official_title>Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate whether infants with total serum bilirubin &gt;
      450 umol/L in the neonatal period and no symptoms or no more than early acute bilirubin
      encephalopathy develop long term sequelae with impairment of motor development, hearing and
      executive function compared with a control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children in both the exposed and the non-exposed group were examined by use of the MABC-2 and
      pure tone audiometry by the responsible examiner for the study, Pernille Vandborg, MD. The
      aim was to see whether the exposed group suffered any long term sequelae to the extreme
      neonatal hyperbilirubinemia, i.e. impaired motor development or hearing impairment, compared
      to a control group. The examinations took place at the local hospital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Motor development</measure>
    <time_frame>Age 5-10 years</time_frame>
    <description>Delayed motor development for children in the exposed group compared to children in the non-exposed group</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">128</enrollment>
  <condition>Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>Exposed group</arm_group_label>
    <description>Children age 5-10 years old who had a total serum bilirubin &gt; 450 umol/L in the neonatal period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposed group</arm_group_label>
    <description>Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Movement assessment battery for children - 2</intervention_name>
    <description>A standardised test developed to identify developmental difficulties in children.</description>
    <arm_group_label>Exposed group</arm_group_label>
    <arm_group_label>Non-exposed group</arm_group_label>
    <other_name>MABC-2</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All children born in Denmark in the period 01.01.2000 - 31.12.2005 with a gestational age
        &gt;= 35 weeks and a total serum bilirubin &gt; 450 umol/L and a matched control group of
        children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age &gt; 35 weeks

          -  Total serum bilirubin &gt; 450 umol/L in the neonatal period

          -  Born in the period 01.01.2000 - 31.12.2005

        Exclusion Criteria:

          -  Acute intermediate or advanced bilirubin encephalopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pernille Vandborg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Børneafdelingen, Aalborg Sygehus, Denmark</affiliation>
  </overall_official>
  <link>
    <url>http://www.aalborgsygehus.rn.dk/Afdelinger/Afsnit1213/Efter+undersøgelser</url>
    <description>A description of the study in Danish</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal hyperbilirubinemia</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Motor development</keyword>
  <keyword>Hearing</keyword>
  <keyword>Executive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

